ASGCT 2021 | Cardiosphere-derived cells in myocardial regeneration

Linda Marban, PhD, Capricor Therapeutics, Beverly Hills, CA, introduces CAP-1002, an allogeneic cardiosphere-derived cell (CDC) therapy that promotes the regeneration of cardiac muscle by stimulating the release of exosomes, thus inducing endogenous repair mechanisms, a reduction in inflammation and ultimately, muscle tissue generation. Clinical trial data indicates that CAP-1002 therapy can result in significant improvements in cardiac and skeletal muscle in patients with Duchenne muscular dystrophy (DMD). CDC-derived extracellular vesicles (EVs) are also being investigated as a therapeutic given their tropism to cardiac and skeletal muscle and ease of storage and delivery. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.